Prespecified secondary analysis of the phase 3 MINT trial (238 adults with generalised myasthenia gravis on a steroid taper): inebilizumab vs placebo lowered exacerbation risk by week 26 (HR 0.41; 95% CI 0.24-0.70), including in AChR+ and MuSK+ subgroups.
Secondary analysisn = 238
Nowak et al. Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial: A Prespecified Analysis of a Randomized Clinical Trial